Harmony Biosciences Holdings, Inc. is a pharmaceutical company based in the United States that specializes in developing therapies for rare neurological diseases. The company's flagship product, WAKIX (pitolisant), targets the treatment of cataplexy in adult narcolepsy patients by increasing histamine signaling in the brain. With a high-risk rating score of 35.6, Harmony Biosciences is committed to ESG principles to ensure environmental sustainability and good governance practices in its operations.